The company said, "The Company is updating its 2023 guidance based on delayed installation schedules and growing financial pressures impacting schedule of deliveries, particularly for international distributors. The Company is reducing its revenue guidance range to approximately zero to 15% growth for fiscal 2023 compared to its previous guidance range of 25% to 40% growth. The Company also updated its Adjusted EBITDA guidance range to a loss of $75 million to $85 million for fiscal 2023 compared to its previous guidance range of a loss of $70 million to $80 million. Cash usage in the first quarter of 2023 was approximately $57 million, primarily due to a working capital impact caused by delays in cash collections from international customers and outlays for inventory. As a result, we anticipate that our cash balance of $86 million will get us into the first quarter of 2024. We intend to decrease cash usage to a range of $25 million to $50 million in 2024, inclusive of our operating expense initiatives."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VRAY:
- ViewRay Falls on Preliminary Q1 Numbers; Outlook Disappoints
- ViewRay Announces Preliminary First Quarter 2023 Results and Updated Fiscal Year 2023 Financial Guidance; Company to Explore Strategic Alternatives to Maximize Shareholder Value
- ViewRay sees no material impact to operations from SVB’s closure, receivership
- ViewRay announces Czech Ministry of Health approval of MRIdian purchase
- ViewRay sees FY23 sees total revenue increase of 25%-40%